SBIR Phase II: Defining the Multimodal Signature of Stroke

SBIR 第二阶段：定义中风的多模态特征

• 批准号: 2039532
• 负责人: Sandra Saldana
• 金额: $ 100万
• 依托单位: ALVA HEALTH, INC.
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-05-15 至 2024-04-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2039532&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Defining; Multimodal

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project falls within the scope of the grand challenges in health informatics. There are excellent protocols for the management and treatment of acute stroke, however, these protocols are only effective once patients have been admitted into the healthcare system. Ischemic stroke affects 700,000 Americans, costs approximately $33 billion annually, and is the fifth leading cause of death and a leading cause of disability in the US. Health care providers, however, have limited interaction with their patients, and these interactions occur in the highly constrained environment of the clinical setting. Physicians have limited control over patient behavior and limited tools to help patients recognize stroke symptoms outside the clinical setting. For patients with high stroke risk, there is currently no system available to monitor stroke symptoms and initiate a response in real-time. Thus, there is a need to monitor patients remotely, where the current systems for stroke response fail to provide coverage. The proposed solution will expand the provision of stroke symptom monitoring to the daily lives of patients. Tracking patients as they go through their daily lives will considerably enrich our knowledge of stroke and will allow extension to monitoring for other neurological and neuropsychiatric disorders and diseases. This Small Business Innovation Research (SBIR) Phase II project addresses the real-time detection of stroke. IV tissue plasminogen activator (tPA) has been an FDA approved therapy since 1995, yet only 5-10% of eligible patients receive this therapy. Arrival time in the emergency room after initial stroke symptoms is directly associated with better outcomes after tPA and endovascular therapy, with a time window of 4.5 hours and 24 hours for these treatments, respectively. Despite massive public health campaigns, identifying symptoms of stroke and activating emergency response systems remains a major challenge. The goal of this project is to develop and test a wearable and computational solution to effectively alert ischemic stroke victims and initiate emergency response in a timely manner. The solution consists of a cloud-based analysis system for real-time detection of stroke onset, enabled by body-worn sensors and a mobile app. Once deployed, the device is expected to dramatically improve stroke emergency response and increase the number of patients arriving in the hospital in time for IV tPA treatment and other reperfusion therapies.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业创新研究（SBIR）第二阶段项目的更广泛的影响/商业潜力福尔斯卫生信息学的重大挑战的范围。有很好的管理和治疗急性中风的协议，但是，这些协议是有效的，一旦病人已经进入医疗保健系统。缺血性中风影响70万美国人，每年花费约330亿美元，并且是美国第五大死亡原因和残疾的主要原因。然而，卫生保健提供者与患者的互动有限，并且这些互动发生在临床环境的高度约束环境中。医生对患者行为的控制有限，帮助患者在临床环境之外识别中风症状的工具有限。对于高中风风险的患者，目前没有系统可用于监测中风症状并实时启动响应。因此，需要远程监测患者，其中用于中风响应的当前系统不能提供覆盖。拟议的解决方案将扩大提供中风症状监测到病人的日常生活。跟踪患者的日常生活将大大丰富我们对中风的了解，并将允许扩展到监测其他神经和神经精神障碍和疾病。这个小型企业创新研究（SBIR）第二阶段项目致力于中风的实时检测。 自1995年以来，IV组织纤溶酶原激活剂（tPA）已成为FDA批准的治疗方法，但只有5-10%的合格患者接受这种治疗。首次卒中症状后到达急诊室的时间与tPA和血管内治疗后的更好结局直接相关，这些治疗的时间窗分别为4.5小时和24小时。尽管开展了大规模的公共卫生运动，但识别中风症状和启动应急响应系统仍然是一项重大挑战。该项目的目标是开发和测试一种可穿戴和计算解决方案，以有效地提醒缺血性中风受害者并及时启动紧急响应。该解决方案包括一个基于云的分析系统，用于实时检测中风发作，由身体佩戴的传感器和移动的应用程序实现。一旦部署，该设备有望极大地改善中风应急反应，并增加及时到达医院接受IV tPA治疗和其他再灌注治疗的患者数量。该奖项反映了NSF的法定使命，并被认为值得通过以下方式获得支持：使用基金会的知识价值和更广泛的影响审查标准进行评估。